Primary Breast Angiosarcoma: Comparative Transcriptome Analysis

Abstract

Primary breast angiosarcoma, with de novo appearance and not associated with exposure to radiation or lymphedema, is a rare pathology representing less than 0.05% of the neoplasms related to this organ. The pathology is characterized by its aggressiveness, poor prognosis, and difficulties in its differential diagnosis. This article reports the case of a 55-year-old white woman with no family history of cancer, with a rapidly growing mass in the left mammary gland that ulcerates and bleeds. It is confirmed as primary breast angiosarcoma by immunostaining in the tumor tissue for CD31, CD34, and FLI-1. In addition, a sample of neoplastic and healthy tissues is collected from the patient for RNA sequencing; the results are contrasted with a tissue sample from a patient with Luminal A subtype of breast cancer, as well as data from other cases of angiosarcoma available in public databases. These findings revealed a genetic profile associated with the immune and inflammatory response in the patient’s sample when compared to available angiosarcoma data; these molecular patterns are consistent with other recent studies. Due to the rarity of the disease, the studies carried out on each patient contribute to the expanding knowledge of the etiology and molecular pathways that are still partially known and continue to be the subject of research. Aside from a comparative transcriptome study, this article aims to provide an update on the state of knowledge about this disease.

The Emerging Role of RNA in Diseases and Cancers

“…Garbo et al reviewed the benefits and the limits of RNA therapeutics by describing the non-coding RNA molecules that are being tested in clinical trials, and by analyzing the delivery strategies for different therapeutical applications [ 5 ]. Rincon-Riveros et al reported an interesting case study in which the authors utilized comparative transcriptome analysis for the diagnosis of primary breast angiosarcoma, a rare cancer representing less than 0.05% of breast cancer cases [ 6 ]. This study highlighted the use of RNA expression to predict an immune and inflammatory response in patients.…”